NewLink Genetics—new organizational and clinical trial strategy for development of its cancer immunotherapy drug indoximod

Indoximod (1-methyl-D-tryptophan) In Chapter 2 of our 2017 book-length report, Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes (published by Insight Pharma Reports), we discussed the major approved and emerging checkpoint inhibitors and checkpoint inhibitor modulators. Most of these, exemplified by the PD-1 inhibitors pembrolizumab (Merck’s Keytruda) and nivolumab (BMS’ Opdivo), [...]

The post NewLink Genetics—new organizational and clinical trial strategy for development of its cancer immunotherapy drug indoximod appeared first on Haberman Associates.